Acta Paediatrica



The five-year survival of children with Down's syndrome differed by associated congenital heart defects and extracardiac malformations, Norway, 1994-2009

Acta Paediatrica SPAE-2017-0776.R1 Regular Article n/a Brodwall, Kristoffer; Universitetet i Bergen Det medisinsk-odontologiske akultet, Department of Global Public Health and Primary Care; Haukeland
Regular Article n/a Brodwall, Kristoffer; Universitetet i Bergen Det medisinsk-odontologiske akultet, Department of Global Public Health and Primary Care; Haukeland
a/a Brodwall, Kristoffer; Universitetet i Bergen Det medisinsk-odontologiske akultet, Department of Global Public Health and Primary Care; Haukeland
rodwall, Kristoffer; Universitetet i Bergen Det medisinsk-odontologiske akultet, Department of Global Public Health and Primary Care; Haukeland
akultet, Department of Global Public Health and Primary Care; Haukeland
Universitetssjukehus, Department of Pediatrics Greve, Gottfried; Haukeland Universitetssjukehus, Department of Heart Disease; Universitetet i Bergen Det medisinsk-odontologiske fakultet, Department of Medical Science Leirgul, Elisabeth; Universitetet i Bergen Det medisinsk-odontologiske akultet, Department of Global Public Health and Primary Care; Haukeland Universitetssjukehus, Department of Heart Disease Klungsøyr, Kari; Universitetet i Bergen Det medisinsk-odontologiske akultet, Department of Global Public Health and Primary Care Holmstrøm, Henrik; Oslo universitetssykehus Rikshospitalet, Department of Pediatrics Vollset, Stein Emil; University of Bergen, Public Health and Primary Health Care Dyen, Nina; Universitetet i Bergen Det medisinsk-odontologiske fakultet, Department of Global Public Health and Primary Health Care
Birth Register, population-based cohort study, childhood mortality, ongenital anomalies, trisomy 21
Die al In (lula loe /o Cay) Bir

SCHOLARONE[™] Manuscripts

The five-year survival of children with Down's syndrome differed by associated congenital heart defects and extracardiac malformations, Norway, 1994-2009

Kristoffer Brodwall^{1,2}, MD, Gottfried Greve^{3,4}, MD, DrMed, Elisabeth Leirgul^{1,4}, MD, PhD, Kari Klungsøyr^{1,5}, MD, DrMed, Henrik Holmstrøm⁶, MD, DrMed, Stein Emil Vollset^{1,7}, MD, DrPH,

Nina Øyen^{1,8}, MD, MPH, DrMed

Affiliations:

- Department of Global Public Health and Primary Care, Faculty of Medicine, University of Bergen, Bergen, Norway;
- 2. Department of Paediatrics, Haukeland University Hospital, Bergen, Norway;
- 3. Department of Medical Science, University of Bergen, Bergen, Norway;
- 4. Department of Heart Disease, Haukeland University Hospital, Bergen, Norway;
- Division of mental and physical health, Norwegian Institute of Public Health, Bergen, Norway;
- 6. Department of Paediatrics, Oslo University Hospital, Oslo, Norway;
- 7. Norwegian Institute of Public Health, Oslo, Norway;
- 8. Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway

Short title: Childhood survival by malformations in Down's syndrome

Corresponding author: Kristoffer Brodwall, Department of Global Public Health and Primary Care, University of Bergen, Kalfarveien 31; PO box 7804, NO-5020 Bergen, NORWAY

Telephone +47 55586098 Fax +47 55586130 E-mail: kristoffer.brodwall@uib.no

Abstract

Aim: We investigated Down's syndrome prevalence in a nationwide birth cohort, focusing on congenital heart defects, associations between heart defects and extracardiac malformations, and survival.

Methods: All births in Norway, 1994-2009, were identified in the Medical Birth Registry, updated with hospital diagnoses, and followed in the Cause of Death Registry until 2014. We estimated birth defect frequencies in Down's syndrome and the general population; the association between heart defects and extracardiac malformations; and hazard ratios for death for different combinations of heart defects and extracardiac malformations.

Results: Among 953,450 births, 1,672 had Down's syndrome (17.6 per 10,000), including 1,251 live births (13.3 per 10,000). Among live births with Down's syndrome, 58% had heart defects and 9% extracardiac malformations. Heart defects were associated with oesophageal atresia (p=0.02) and Hirschsprung's disease (p=0.03), but with no other malformations. The five-year survival for Down's syndrome children increased from 91.8% (1994-1999) to 95.8% (2000-2009), p=0.006. Overall it was 92.0% with heart defects and 97.4% without. Five-year mortality was 13-28 times higher in those with severe heart defects and extracardiac malformations than in those without malformations.

Conclusion: Childhood survival in Down's syndrome improved, but mortality was still high in children with severe heart defects combined with extracardiac defects.

Key words: birth register, childhood mortality, congenital anomalies, population-based cohort study, trisomy 21

Key notes:

- Children with Down's syndrome have increased risk of congenital heart defects and extracardiac malformations, potentially affecting their risk of childhood death.
- Among live births with Down's syndrome in Norway 1994-2009, the risk of congenital heart defects was not associated with the risk of extracardiac malformations, except for oesophageal atresia and Hirschsprung's disease.
- Severe congenital heart defects predicted increased mortality in children with Down's syndrome, especially when combined with extracardiac malformations.

Word count: 3,150

P ICZ OZL

INTRODUCTION

The birth prevalence of Down's syndrome is about one per 1,000 births, with an increasing total birth prevalence explained by increasing maternal age (1). Down's syndrome is associated with congenital heart defects (CHD), in particular atrioventricular septal defect (AVSD) (2–7), and also extracardiac malformations (ECM), especially gastrointestinal malformations (5,6). It has not been established whether the risks of cardiac and extracardiac malformations are associated or independent in Down's syndrome.

Mortality is linked to malformations in Down's syndrome (8–11). Despite increasing proportion of pregnancy termination due to foetal Down's syndrome in Europe, the proportion of live births with associated malformations remains unchanged (6). Therefore, it is important to assess further the association between malformations and childhood mortality in Down's syndrome, to identify individuals at highest risk of premature death.

Norway's national health registers and population registers provide the opportunity to investigate the prevalence of Down's syndrome in live births, stillbirths and terminated pregnancies. We aimed at estimating the specific cardiac phenotypes in Down's syndrome, and the association between CHD and ECM in children with Down's syndrome. Finally, following the cohort in the Cause of Death Registry enabled us to study the influence of CHD and ECM on survival among children with Down's syndrome.

METHODS

Data sources

Since 1967, the Medical Birth Registry of Norway has registered information on live births and stillbirths after 16 weeks of gestation. The registry has received notifications

Acta Paediatrica

of every termination of pregnancy for foetal anomaly (TOPFA) since December 1998, and occasionally earlier, reported as stillbirths (12). The unique personal identification number was used to update the Medical Birth Registry with information on CHD from three additional sources: Diagnostic and procedural codes from the hospitals' Patient Administrative System for all hospitalizations in Norway 1994-2009, if at least one diagnosis was related to the cardiovascular system (13); diagnostic and procedural codes in the clinical database for children with heart disease from Oslo University Hospital; and diagnostic codes in the Cause of Death Registry of Norway. This study is part of the Cardiovascular Disease in Norway project (<u>www.cvdnor.no</u>) (13). The study was approved by the Regional Committee for Medical and Health Research Ethics, Western Norway (2009/861-14).

Study population

Among 954,413 births from 1994 through 2009, we excluded 963 births with chromosomal aberrations other than Down's syndrome (International Classification of Diseases, Eighth Revision 759.1-759.2, 759.4-759.8; Ninth Revision 758.1-758.9, 759.3-759.8; Tenth Revision Q91.0-99.9), leaving 953,450 for analysis. Information of Down's syndrome, CHD and ECM was retrieved from the data sources mentioned above until 31 December 2009. Information on date of death was collected from the Cause of Death Registry until 2 May 2014.

Ascertainment of Down's syndrome

Individuals with Down's syndrome were ascertained from the four data sources mentioned above, using codes in the International Classification of Diseases, Eighth Revision (759.3), Ninth Revision (758.0) and Tenth Revision (Q90.0, Q90.1, Q90.2 or Q90.9).

Congenital heart defects

Information about CHD was retrieved from the four data sources and classified as described in detail by Leirgul et al (14). Individuals with one or more CHD were assigned one cardiac phenotype by using the hierarchical classification system introduced by Botto et al (15) and later modified by Leirgul et al (14). Atrial septal defects (ASD) of the primum type were classified as AVSD, and isolated ASD secundum as ASD. Persistent ductus arteriosus (PDA) and ASD were only ascertained if recorded at postnatal age >6 weeks or if surgically corrected. In this study, we define severe CHD as any CHD except ASD, ventricular septal defect (VSD) and PDA.

Extracardiac malformations

Information on ECM was identified from the Medical Birth Registry and Cause of Death Registry using codes in the International Classification of Diseases (Table S1). ECM diagnoses were classified by organ systems according to the structure in the International Classification of Diseases, Tenth Revision, chapter XVII: malformations of the nervous system; eyes, ears, face, and neck; respiratory system; cleft lip-palate; digestive system; genital organs; urinary system. Subcategories were analysed if there were at least seven children with Down's syndrome.

Statistical analyses

The total birth prevalence of Down's syndrome was calculated for live births, stillbirths, and TOPFA by each year of birth and adjusted for maternal age in years, handled as continuous variables in a generalised linear model with the log-link function for binomial outcome. Prevalence ratios expressed the ratios between birth prevalences of congenital malformations in Down's syndrome, and birth prevalences of the same

Acta Paediatrica

malformations in live births without chromosomal aberrations. When adjusting for maternal age and year of birth, prevalence ratios were estimated in generalised linear models with the log-link function for binomial outcome. Time trends were evaluated with generalised linear models, using year of birth as a continuous variable. To estimate associations between CHD and ECM, we used logistic regression to calculate odds ratio with 95% confidence interval (95%CI). For associations between CHD and ECM for which odds ratio were not estimable (due to empty cells), Fisher's exact test was used to calculate a p-value for the association.

We estimated five-year survival for live births, censoring individuals at loss to follow-up (5.5% of live births were lost to follow-up before five years of age) due to emigration or birth after May 2009 (non-informative censoring). When comparing different mortality rates, Poisson regression was used to calculate p-values. We estimated childhood death risk by CHD and ECM groups, using Nelson-Aalen's cumulative hazard and Cox' proportional hazard regression, adjusted for year of birth as (one-year categories). Survival was displayed with Kaplan-Meier curves. All statistical analyses were performed with Stata 14.0 (StataCorps, Texas, USA).

RESULTS

Among 953,450 births in the period 1994-2009, there were 943,477 live births, 7,914 stillbirths and 2,059 TOPFAs. Down's syndrome was diagnosed in 1,672 births (total birth prevalence 17.6 per 10,000) and in 1,251 live births (live birth prevalence 13.3 per 10,000 births). The total birth prevalence of Down's syndrome gradually increased throughout the 16-year period: the annual increase in relative risk was 1.04 (95% confidence interval (CI) 1.03-1.05). However, there was no significant time trend in the total birth prevalence of Down's syndrome, when adjusting for maternal age and stratifying on the time periods without (1994-1998) and with (1999-2009) mandatory

reporting of TOPFA (relative risk 1.03; 95%CI 0.96-1.10 and relative risk 1.01; 95%CI 0.99-1.02, respectively). Since 1999, the proportion of Down's syndrome pregnancies being terminated has increased with an average of 7.2% annually (p=0.000). Throughout the study period, there was a weak, annual increase in the live birth prevalence of Down's syndrome (relative risk 1.01; 95%CI 1.00-1.03) (Figure 1).

Proportion with CHD in births with Down's syndrome

CHD were highly prevalent among births with Down's syndrome: 786/1,672 (47.0%) had CHD among all births, 724/1,251 (57.9%) among live births, 12/49 (24.5%) among stillbirths and 50/372 (13.4%) among terminated pregnancies. In stillbirths/TOPFA with Down's syndrome, the probability of a CHD diagnosis decreased by shorter gestational age (P<0.001). Due to a probable underreporting of CHD in stillbirths/TOPFA the following analyses were restricted to live births.

Specific types of cardiac defects in Down's syndrome

In live births, CHD was 47 times more prevalent in Down's syndrome than in births without chromosome aberrations (Table 1). Most types of CHD were overrepresented in Down's syndrome compared to the background population (prevalence ratios ranged 2.7-850), except for transposition of the great arteries, hypoplastic left heart syndrome and hypoplastic right heart syndrome. The prevalence ratios were unchanged after adjusting for maternal age and year of birth. AVSD was particularly prevalent, found in 20.3% of Down's syndrome live births, which means that the birth prevalence was 850 times greater than the AVSD prevalence in live births without chromosomal aberrations. In Down's syndrome, AVSD was recorded as an isolated cardiac defect in nearly all affected children (254 of 256), in contrast to the background population where 16.4% of the AVSD occurred in combination with another cardiac defect. For children with

Down's syndrome, there were no temporal changes in the prevalence of CHD overall, AVSD, ASD, VSD, nor for PDA (p values 0.638, 0.905, 0.845, 0.250 and 0.533, respectively).

Extracardiac malformations

ECMs were diagnosed six times more frequently in live births with Down's syndrome than without chromosomal aberrations (911 per 10,000 versus 146 per 10,000, Table 2). Malformations of the gastrointestinal tract were particularly frequent in Down's syndrome (prevalence ratio 19, 95% CI 15-24).

Association between congenital heart defects and extracardiac malformations The co-occurrence between CHD and ECM was estimated among individuals with Down's syndrome and in the general population; the CHD risk was calculated for subgroups defined by presence or absence of ECM (Table 3). In live births without chromosomal aberrations there was a strong association between CHD and ECM (odds ratio 5.6; 95%CI 5.2-6.0), with CHD associated with every type of ECM. In Down's syndrome, however, 7/7 cases of oesophageal atresia and 10/11 cases of Hirschsprung's disease were associated with CHD (p-value 0.02 and p-value 0.03, respectively, on Fisher's exact test).

Childhood mortality in Down's syndrome

During follow-up of 1,251 live births with Down's syndrome until 2 May 2014 (mean follow-up time 11.2 years), 16 emigrated and 78 died, of whom 68 died before 5 years of age and 5 died between five years and 15 years of age. Among the children with CHD who died, more than half (31 of 58) had undergone cardiac surgery or other type of cardiac intervention at least once. The overall one-year survival for children with

Acta Paediatrica

Down's syndrome was 96.3% (46 deaths). In those with CHD the one-year survival was 94.9%, and in those without CHD 98.3% (p=0.003). The five-year survival for children with Down's syndrome increased from 91.8% for births 1994-1999 to 95.8% for births 2000-2009 (p=0.006). Overall, the five-year survival was 94.2%, with lower survival for children with CHD (92.0%) than without CHD (97.4%) (p<0.001). For comparison, five-year survival in the general population was 93.1% for individual with CHD and 99.6% for individuals without CHD. Comparing with the general population, survival was significantly poorer for children with Down's syndrome without CHD (p<0.001), but not for those with CHD (p=0.294).

Mortality estimates in Down's syndrome by CHD and ECM

In children with Down's syndrome, the hazard ratio of death before age five years was similar for those with septal defects or PDA, as compared with children with Down's syndrome without CHD (Table 4). The five-year hazard ratios of death was highest for children with conotruncal defects, followed by AVSD and remaining types of CHDs. Mortality was especially high for children with Down's syndrome who had CHD in combination with ECM. In this category, 93% of the childhood deaths occurred before the first birthday. Most childhood deaths occurred before five years of age, for all children with Down's syndrome and any combination of CHD and ECM. Very few children with Down's syndrome died between five and 15 years of age (Figure 2), but with complete follow-up for 28% of the cohort; that is children born before 1999.

DISCUSSION

In a national cohort of around 950,000 births 1,672 were identified with Down's syndrome over a 16 year period. The total birth prevalence of Down's syndrome was 17.6 per 10,000, and the live birth prevalence 13.3 per 10,000. These numbers were

Acta Paediatrica

comparable to previous estimates (2,3,5). In Down's syndrome live births, more than half had CHD, among them one-third had AVSD. Extracardiac malformations (ECM) were found in 9%. Most of the ECMs were malformations of the gastrointestinal tract. Generally, CHD and ECM were *not* associated in children with Down's syndrome, as opposed to what was seen in the general population. Survival beyond five years of age was 94.2% for children with Down's syndrome overall, but differed by CHD and ECM subgroups, and was poorest for those with severe types of CHD combined with ECM.

The total birth prevalence of Down's syndrome gradually increased through the study period, mainly attributable to an increasing maternal age. The stable live birth prevalence of Down's syndrome may be explained by more frequent use of termination of pregnancies with foetal Down's syndrome (1,6). In Norway, pregnant women aged 38 years or older at due date qualify for prenatal screening for foetal aneuploidy. In the present study, the proportion of Down's syndrome foetuses with a registered CHD diagnosis was low if the pregnancy was terminated or ended in stillbirth. This lower proportion of CHD could be explained by diagnostic inaccuracy in early foetal life (6,16), and/ or by lower autopsy rates in Down's syndrome stillbirths and terminations. Due to this possible underreporting, analyses of CHD and ECM were restricted to live births.

The proportion of children with Down's syndrome having CHD (58%) showed no temporal change; neither did the prevalence of the most frequent groups of CHD (AVSD, ASD, VSD, and PDA), as opposed to what was seen in a recent Swedish study (17). Children with Down's syndrome had increased risk of most types of CHD. However, transposition of the great arteries was not identified in any individual with Down's syndrome in our study. This is consistent with findings pointed out in most other studies (5). We found AVSD (20.3%), isolated ASD (10.8%) and isolated VSD (10.6%) to be the dominating types of CHD in Down's syndrome. Expressed as proportions of children with CHD and Down's syndrome AVSD, ASD and VSD accounted for 35.1%,

18.7% and 18.4%, respectively. These proportions were within the range of most previous estimates (3–5,7). One in every six chromosomally normal individuals with AVSD had an additional CHD, whereas AVSD was isolated in most of those with Down's syndrome in our study. Similar findings have been reported previously (18).

In the general population, CHD is known to be associated with ECM (19) which we confirmed in our cohort, but to our knowledge this association has not been studied in Down's syndrome previously. All children with Down's syndrome and oesophageal atresia had CHD, and 10 of 11 children with Down's syndrome and Hirschsprung's disease had CHD. In the general population, the association between oesophageal atresia and CHD is well known as part of the VACTERL association, which stands for vertebral defect, anorectal malformation, cardiac defect, tracheoesophageal fistula, renal anomaly, radial dysplasia and limb defects (20). But in the present study none of the seven children with Down's syndrome, oesophageal atresia and CHD had other diagnoses related to the VACTERL association. The association between Hirschsprung's disease and CHD in children with Down's syndrome was consistent with numbers reported in other studies (7,8), but the association has not been tested statistically previously. Other types of ECM were not significantly associated with CHD in children with Down's syndrome. This finding could indicate that the trisomy is so strong a risk factor that other risk factors that differ among individuals with Down's syndrome become relatively unimportant for the development of congenital malformations.

The five-year mortality for children with Down's syndrome was 5.8%. The mortality was significantly increased for those with CHD, in line with previous studies (9,11,21–24). We found that the risk of death in early childhood was further increased if the CHD was combined with an ECM, a finding which to our knowledge has not previously been described. The mortality was especially high for children with Down's

http://mc.manuscriptcentral.com/spae Email: mail@actapaediatrica.se

Acta Paediatrica

syndrome and conotruncal defects, AVSD, or other severe types of CHD; that is, any CHD except PDA, ASD and VSD. But 89% of these children were still alive at five years of age.

We found increased early childhood mortality for children with Down's syndrome, compared to the general population, but not when comparing children with Down's syndrome and CHD with chromosomally normal children with CHD. The oneyear survival for children with Down's syndrome in our cohort was 96%. This is higher than what was found for children with Down's syndrome in northern Sweden 1973-80 (85.4%) (8,24), Italy 1978-84 (80%) (22), Ireland 1980-89 (88%) (25), Denmark 1968-2009 (89%) (9), Western Australia 1980-96 (92%) (11) and the United States 1983-2003 (93%) (10), but it is similar to what was found in northern Sweden 1995-98 (97.7%) (24), the Netherlands 2003 (96%) (23) and Thailand 2007-12 (96%) (21). Survival of children with Down's syndrome improved over time in our study, and extrapolation of this time trend to the aforementioned studies can possibly explain different estimates. This time trend might reflect changing attitude to surgical repair of congenital malformations in children with Down's syndrome over the past decades (26).

The major strengths of this study were the large number of individuals with Down's syndrome and inclusion of stillbirths and TOPFA for prevalence rates. Further, our study was strengthened by health information collected from population based registers with compulsory notification and updated with diagnoses from clinical registers. Because health care is essentially free of charge in Norway there is universal access ensuring completeness of the data.

Individuals with Down's syndrome were predominantly ascertained from the Medical Birth Registry (90.3%). The registration of Down's syndrome in this registry has been validated for the period 2001-2005 by comparing with laboratory data from the departments of medical genetics in Norway (27). The Medical Birth Registry had

http://mc.manuscriptcentral.com/spae Email: mail@actapaediatrica.se

Acta Paediatrica

registered Down's syndrome for 81.6% of the laboratory confirmed cases, and 90.2% of Down's syndrome cases in the Medical Birth Registry had laboratory verification. Presumably, our ascertainment has identified 91% of the total number of individuals with Down's syndrome, based on an estimation method for the expected proportion of Down's syndrome in a specified birth cohort (28). A weakness, however, was the lack of information about karyotype, preventing us from distinguishing between complete trisomy 21, translocations and mosaicism.

Limitations in the present study included a likely underreporting of congenital malformations in stillbirths and terminations due to foetal anomalies. For this reason, we restricted the main analyses to live births, which might have introduced *live birth bias* (29). Misclassifications were possible, particularly regarding ECM which has not been fully validated in the Medical Birth Registry, but misclassification was not likely to be extensive, since we found prevalence of ECM in Down's syndrome similar to previous studies (6,7). Finally, increased mortality associated with multiple birth defects in children with Down's syndrome could be due to complications of the birth defects, but it could also be explained by clinicians withholding treatment for children with multiple medical challenges. We missed data that could have distinguished between these two explanations.

CONCLUSION

In a complete national birth cohort, the total birth prevalence of Down's syndrome increased in Norway, 1994-2009. The live birth prevalence, however, was stable around 13.3 per 10,000, due to the increasing proportion of pregnancy termination for prenatally diagnosed Down's syndrome. More than half of live births with Down's syndrome had CHD, of which AVSD was the most frequent, followed by ASD and VSD. In children with Down's syndrome, CHD was associated with oesophageal atresia and

Acta Paediatrica

Hirschsprung's disease, but not with any other ECM, as opposed to births without <text> chromosomal aberrations. The five-year survival for children with Down's syndrome improved during the study period, and overall it was 97.4% for those without CHD, 93.3% for those with CHD without ECM and 80.6% for those with both CHD and ECM. http://mc.manuscriptcentral.com/spae Email: mail@actapaediatrica.se

Acknowledgments

The authors thank Tomislav Dimoski at The Norwegian Knowledge Centre for the Health Services, Oslo, Norway for his contribution by developing the software necessary for obtaining data from Norwegian hospitals, conducting the data collection and quality assurance of data in this project, and Dr Petter Hagemo for construction and maintenance of the clinical database for CHDs at the Oslo University Hospital, Norway, and statistician Tatiana Fomina, PhD, Department of Global Health and Primary Care, University of Bergen, Norway, for programming the algorithm that maps CHDs into embryologically related defect phenotypes. Dr Brodwall received funding from the Western Norway Regional Health Authority (911764). This work was supported by Research Council Norway (190858/V50) to Dr Øyen.

List of abbreviations

- ASD atrial septal defect
- AVSD atrioventricular septal defect
- CHD congenital heart defect
- CI Confidence interval
- ECM –extracardiac malformations
- PDA isolated persistent ductus arteriosus
- TOPFA termination of pregnancy for foetal anomaly
- VSD ventricular septal defect

FINANCE

This study did not receive any specific funding.

CONFLICTS OF INTEREST

The authors have no conflicts of interest to declare.

References

- Cocchi G, Gualdi S, Bower C, Halliday J, Jonsson B, Myrelid Å, et al. International trends of Down syndrome 1993-2004: Births in relation to maternal age and terminations of pregnancies. *Birth Defects Res A Clin Mol Teratol.* 2010;88(6):474–9.
- Cleves MA, Hobbs CA, Cleves PA, Tilford JM, Bird TM, Robbins JM. Congenital defects among liveborn infants with Down syndrome. *Birth Defects Res A Clin Mol Teratol.* 2007;79(9):657–63.
- Freeman SB, Taft LF, Dooley KJ, Allran K, Sherman SL, Hassold TJ, et al. Populationbased study of congenital heart defects in Down syndrome. *Am J Med Genet*. 1998;80(3):213–7.
- Freeman SB, Bean LH, Allen EG, Tinker SW, Locke AE, Druschel C, et al. Ethnicity, sex, and the incidence of congenital heart defects: a report from the National Down Syndrome Project. *Genet Med.* 2008;10(3):173–80.
- Torfs CP, Christianson RE. Anomalies in Down syndrome Individuals in a large population-based registry. *Am J Med Genet*. 1998;77(5):431–8.
- Morris JK, Garne E, Wellesley D, Addor M-C, Arriola L, Barisic I, et al. Major congenital anomalies in babies born with Down syndrome: A EUROCAT population-based registry study. *Am J Med Genet A*. 2014;164A(12):2979–86.
- Torfs CP, Christianson RE. Maternal risk factors and major associated birth defects in infants with Down syndrome. *Epidemiology*. 1999;10(3):264–70.
- 8. Frid C, Drott P, Lundell B, Rasmussen F, Annerén G. Mortality in Down's syndrome in relation to congenital malformations. *J Intellect Disabil Res.* 1999;43(3):234–41.
- Zhu JL, Hasle H, Correa A, Schendel D, Friedman JM, Olsen J, et al. Survival among people with Down syndrome: a nationwide population-based study in Denmark. *Genet Med.* 2012:1–6.

- 10. Kucik JE, Shin M, Siffel C, Marengo L, Correa A. Trends in survival among children with Down syndrome in 10 regions of the United States. *Pediatrics.* 2013;131(1):e27-36.
- 11. Leonard S, Bower C, Petterson B, Leonard H. Survival of infants born with Down's syndrome: 1980-96. *Paediatr Perinat Epidemiol.* 2000;14(2):163–71.
- 12. Irgens LM. The Medical Birth Registry of Norway: an essential resource in perinatal research. *Tidsskr Nor Lægeforen.* 2002;122:2546–9.
- Sulo G, Igland J, Vollset SE, Nygård O, Øyen N, Tell GS. Cardiovascular disease and diabetes mellitus in Norway during 1994-2009 CVDNOR – a nationwide research project. *Nor Epidemiol.* 2013;23(1):101–7.
- 14. Leirgul E, Fomina T, Brodwall K, Greve G, Holmstrøm H, Vollset SE, et al. Birth prevalence of congenital heart defects in Norway 1994-2009—A nationwide study. *Am Heart J.* 2014;168(6):956–64.
- Botto LD, Lin AE, Riehle-Colarusso T, Malik S, Correa A. Seeking causes: classifying and evaluating congenital heart defects in etiologic studies. *Birth Defects Res A Clin Mol Teratol.* 2007;79(10):714–27.
- ter Heide H, Thomson JDR, Wharton GA, Gibbs JL. Poor sensitivity of routine fetal anomaly ultrasound screening for antenatal detection of atrioventricular septal defect. *Heart.* 2004;90(8):916–7.
- Bergström S, Carr H, Petersson G, Stephansson O, Bonamy A-KE, Dahlström A, et al. Trends in congenital heart defects in infants with Down syndrome. *Pediatrics*. 2016;138(1).
- Hartman RJ, Riehle-Colarusso T, Lin A, Frías JL, Patel SS, Duwe K, et al. Descriptive study of nonsyndromic atrioventricular septal defects in the National Birth Defects Prevention Study, 1997-2005. *Am J Med Genet A*. 2011;155A(3):555–64.
- 19. Stoll C, Dott B, Alembik Y, Roth M-P. Associated noncardiac congenital anomalies among cases with congenital heart defects. *Eur J Med Genet.* 2015;58(2):75–85.

60

1	17
2 3	20. La Placa S, Giuffrè M, Gangemi A, Di Noto S, Matina F, Nociforo F, et al. Esophageal
4 5	
6	atresia in newborns: a wide spectrum from the isolated forms to a full VACTERL
7 8	phenotype? Ital J Pediatr. 2013;39:45.
9 10	21. Layangool T, Sangtawesin C, Kirawittaya T, Prompan W, Prachasilchai P,
11 12	Pechdamrongsakul A. Survival analysis of Down syndrome with congenital heart
13 14	disease: a 5-years registry at QSNICH. J Med Assoc Thai. 2014;97 Suppl 6:S108-14.
15 16	22. Mastroiacovo P, Bertollini R, Corchia C. Survival of children with Down syndrome in Italy.
17 18	<i>Am J Med Genet.</i> 1992;42(2):208–12.
19 20	23. Weijerman ME, van Furth AM, Vonk Noordegraaf A, van Wouwe JP, Broers CJM,
21 22	Gemke RJBJ. Prevalence, neonatal characteristics, and first-year mortality of Down
23 24	syndrome: A national study. <i>J Pediatr.</i> 2008;152(1):15–9.
25 26	24. Frid C, Drott P, Otterblad Olausson P, Sundelin C, Annerén G. Maternal and neonatal
27 28	
29	factors and mortality in children with Down syndrome born in 1973-1980 and 1995-1998.
30 31	Acta Paediatr. 2004;93(1):106–12.
32 33	25. Hayes C, Johnson Z, Thornton L, Fogarty J, Lyons R, O'Connor M, et al. Ten-year
34 35	survival of Down syndrome births. Int J Epidemiol. 1997;26(4):822–9.
36 37	26. Champagne CR, Lewis M, Gilchrist DM. Should we mend their broken hearts? The
38 39	history of cardiac repairs in children with Down syndrome. <i>Pediatrics</i> . 2014;134:1048–50.
40 41	27. Melve KK, Lie RT, Skjaerven R, Van Der Hagen CB, Gradek GA, Jonsrud C, et al.
42 43	Registration of Down syndrome in the Medical Birth Registry of Norway: validity and time
44 45	
46	trends. Acta Obstet Gynecol Scand. 2008;87(8):824–30.
47 48	28. Loane M, Dolk H, Garne E, Greenlees R. Paper 3: EUROCAT data quality indicators for
49 50	population-based registries of congenital anomalies. Birth Defects Res A Clin Mol
51 52	<i>Teratol.</i> 2011;91(Suppl 1):S23-30.
53	
54 55	
56	

29. Liew Z, Olsen J, Cui X, Ritz B, Arah OA. Bias from conditioning on live birth in pregnancy cohorts: An illustration based on neurodevelopment in children after prenatal exposure to

.2015;44(1):345-54

Figure Legends

Figure 1:

Legend: Time trend for total birth prevalence (per 10,000 births) of Down's syndrome by year of birth, based on 953,450 births in Norway 1994-2009.

Footnote: AVSD, atrioventricular septal defect; CHD, congenital heart defects; TOPFA: Termination of Pregnancy for Foetal Anomaly.

Figure 2:

Legend: Kaplan-Meier survival estimates for children with Down's syndrome born in Norway 1994-2009. The estimates are based on 1,251 live births with Down's syndrome follow-up until May 2nd 2014.

Footnote: Severe CHD is defined as any CHD, excluding ASD, VSD and PDA.

ASD, atrial septal defect; CHD, congenital heart defects; ECM, extracardiac malformations;

PDA, persistent ductus arteriosus; VSD, ventricular septal defect.



			´s syndrome 1,251	Normal chromosomes 942,226		
(Cardiac phenotype	Ν	Prevalence	per 10,000 births	PR ^a	(95% CI)
)	With any type of CHD	724	5,787	124	47	(44 - 49)
	Heterotaxia	1	8.0	1.4	5.7	(0.8 - 41)
3	Conotruncal defect	39	312	10	30	(22 - 42)
+	Transposition of the great arteries	0		3.2		
;	Tetralogy of Fallot ^b	14	112	2.4	48	(28 - 81)
7	Double outlet right ventricle	2	16	0.6	26	(6.5 - 108)
3	Conotruncal VSD	12	96	1.5	66	(37 – 119)
,	Aortic hypoplasia	7	56	1.8	32	(15 - 67)
	Other conotruncal defects ^c	4	32	0.9	37	(14 - 101)
2	Atrioventricular septal defect	254	2,030	2.4	850	(717 - 1008)
3	Anomalous pulmonary venous return	2	16	1.1	15	(3.6 - 60)
+ - ; _	Left ventricular outflow tract obstruction	11	88	7.3	12	(6.6 - 22)
; _	Hypoplastic left heart syndrome	0		1.6		
'	Aortic valve stenosis	1	8.0	3.0	2.7	(0.4 - 19)
	Coarctation of the aorta	10	80	2.7	30	(16 - 56)
)	Right ventricular outflow tract obstruction	3	24	5.3	4.5	(1.5 - 14)
	Hypoplastic right heart syndrome	0	4.	0.7		
2	Ebstein's anomaly	1	8.0	0.6	14	(1.9 - 99)
	Pulmonary valve stenosis/ atresia	2	16	4.0	4.0	(1.0 - 16)
5	Septal defects	322	2,574	61	43	(39 - 47)
	ASD, isolated	135	1,079	13	85	(72 - 101)
3	VSD, isolated, any type	133	1,063	46	23	(20 - 27)
,	VSD, perimembranous	57	456	4.7	96	(73 – 126)
)	VSD, muscular	9	72	4.6	16	(8.1 - 30)
	VSD, unspecified location	67	536	36	15	(12 - 19)
	ASD + VSD	51	408	1.3	326	(235 - 450)
	Unspecified septal defects	3	24	0.9	28	(8.7 - 87)
	Persistent ductus arteriosus, isolated	60	480	24	20	(15-25)
,	At term gestation	44	440	11	41	(30-55)
3	In preterm birth	16	640	208	3.1	(1.9 - 5.0)
, –	Other specified congenital heart defects	12	96	6.2	16	(8.8 – 27)
) –	Unspecified congenital heart defects	20	160	5.0	32	(20-50)

• •• c ...

a) Unadjusted prevalence ratio (PR) with 95% confidence interval (CI), comparing the prevalence of CHD in live births with Down's syndrome with the prevalence of the same type of CHD in live births without chromosomal aberrations (reference). Adjusted PR for maternal age and year of birth were unchanged (not shown).

b) Including tetralogy of Fallot in combination with atrioventricular septal defect

c) Including truncus arteriosus, aortopulmonary window, and interrupted aortic arch type B and C.

ASD, Atrial septal defect; CHD, congenital heart defect; CL, confidence interval; VSD, Ventricular septal defect; PR, prevalence ratio.

1	
2	
2	
3 4	
5 6	
0	
/	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19 20	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29 30	
30	
31	
32	
33	
34 35	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	

		s syndrome 1,251	Normal chi 942	romosomes ,226		
Extracardiac malformation	Ν	Per 10,000	Ν	Per 10,000	Prevalence ratio ^a	(95%CI)
One or more extracardiac malformations	114	911	13,741	146	6.2	(5.2-7.4)
Nervous system malformations	2	16	819	8.7	1.8	(0.5-7.4)
Eyes, ears, face, neck malformations	5	40	1,407	15	2.7	(1.1-6.4)
Respiratory system malformations	10	80	774	8.2	9.7	(5.2-18)
Cleft lip-palate	3	24	1,714	18	1.3	(0.4-4.1)
Digestive system malformations	81	647	3,211	34	19	(15-23)
Oesophageal atresia/ stenosis	7	56	204	2.2	26	(12-55)
Small intestine	43	344	146	1.5	222	(159-310)
Duodenal atresia/ stenosis ^b	30	240	63	0.7	341	(222-524)
Large intestine	14	112	196	2.1	54	(31-92)
Rectal/ anal atresia/ stenosis ^b	13	104	137	1.5	68	(39-120)
Hirschsprung's disease	11	88	135	1.4	61	(33-113)
Genital organs malformations	9	72	4,746	50	1.4	(0.7-2.7)
Urinary system malformations	8	64	1,632	17	3.7	(1.8-7.4)

a) Unadjusted prevalence ratio (PR) with 95% confidence interval (CI), comparing the prevalence of extracardiac malformation in live births with Down's syndrome with the prevalence of the same type of extracardiac malformation in live births without known chromosomal aberrations (reference).

b) Registered for births from 1999 to 2009.

CI, confidence interval.

		724 wi	own´s syno th CHD, 5 h ECM, 1,	527 with		11,676 with		0,550 w	42,226: ithout CHD ithout ECM	Interaction ^b
Extracardiac malformation	CHD	N	Per 10,000	OR ^a	(95%CI)	N	Per 10,000	OR ^a	(95%CI)	
One or more extracardiac malformations	Yes No	75	1,036 740	1.4	(1.0-2.2)	849 12,892	727	5.6	(5.2-6.0)	< 0.0001
Nervous system malformations	Yes No	1	14 19	0.7	(0.0-12)	104 715	<u>89</u> 7.7	12	(9.5-14)	0.045
Eyes, ears, face, neck malformations	Yes No	3	41 38	1.1	(0.2-6.6)	65 1,342	56 14	3.9	(3.0-5.0)	0.17
Respiratory system malformations	Yes No	8	110 38	2.9	(0.6-14)	100 674	86 7.2	12	(9.7-15)	0.061
Cleft lip-palate	Yes No	2	28 19	1.5	(0.1-16)	113 1,601	97 17	5.7	(4.7-6.9)	0.27
Digestive system malformations	Yes No	54 27	746 512	1.5	(0.9-2.4)	350 2,861	<u>300</u> 31	10	(9.0-11)	< 0.0001
Oesophageal atresia/ stenosis	Yes No	7 0	97 0	NE		91 113	78 1.2	65	(49-85)	NE
Small intestine	Yes No	26 17	359 323	1.1	(0.6-2.1)	34 112	29 1.2	24	(17-36)	<0.0001
Duodenal atresia/ stenosis ^c	Yes No	17 13	235 247	1.0	(0.5-2.1)	16 47	14 0.5	25	(14-44)	<0.0001
Large intestine	Yes No	777	97 133	0.7	(0.3-2.1)	42 154	36 1.7	22	(16-31)	<0.0001
Rectal/ anal atresia/ stenosis ^c	Yes No	7 6	97 114	0.9	(0.3-2.6)	35 102	30 1.1	25	(17-37)	< 0.0001
Hirschsprung's disease	Yes No	10 1	138 19	7.4	(0.9-58)	17 118	15 1.3	11	(6.9-19)	0.60
Genital organs malformations	Yes No	6 3	83 57	1.5	(0.4-5.9)	149 4,597	128 49	2.6	(2.3-3.1)	0.42
Urinary system malformations	Yes No	53	69 57	1.2	(0.3-5.1)	127 1,505	109 16	6.8	(5.7-8.1)	0.017
Vithout extracardiac malformation Reference)	Yes No	649 488				10,827 917,658				0.017

the same type of extracardiac malformations live births without CHD, calculated separately for births with Down's syndrome and births without known http://mc.manuscriptcentral.com/spaeEmail: mail@actapaediatrica.se

	-	
		chromosomal aberrations.
1	1	
	b)	P-value for homogeneity between the OR values in births with Down's syndrome and the OR values in births without chromosomal aberrations,
2		calculated with the Mantel-Haenszel's test.
3		
	c)	Registered for births from 1999 to 2009.
4		
5	CHD /	congenital heart defect; CI, confidence interval; NE, not estimable; OR, odds ratio.
6	CHD, (congential near detect, C1, confidence interval, 10E, not estimatic, OK, odds fatto.
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		http://mc.manuscriptcentral.com/spae Email: mail@actapaediatrica.se
46		
47		

Malformations	ECM	Deaths	N at risk ^a	Risk of death ^b	(95%CI)	HR ^c	(95%CI)
No CHD					· · · · ·		<u> </u>
	No	11	488	2.3%	(1.3 - 4.1%)	1	(Reference)
	Yes	2	39	5.2%	(1.3 - 21%)	2.6	(0.6-12)
Isolated persistent ductus							
arteriosus	No	1	48	2.1%	(0.3 - 15%)	0.9	(0.1-6.7)
	Yes	0	12	-		-	
Septal defects ^d							
	No	9	296	3.1%	(1.6 - 6.0%)	1.5	(0.6-3.5)
	Yes	3	26	12%	(3.9 - 37%)	3.8	(0.8-17)
Atrioventricular septal defect							
	No	22	234	9.9%	(6.5 - 15%)	4.2	(2.0-8.7)
	Yes	4	20	22%	(8.1 - 58%)	13	(3.9-40)
Conotruncal defects ^e							
	No	5	31	17%	(7.2 - 42%)	7.4	(2.6-21)
	Yes	4	8	63%	(23 - 100%)	28	(8.9-88)
CHD, remaining types ^f							
	No	4	40	10%	(3.9 - 28%)	4.3	(1.4-13)
	Yes	3	9	38%	(12 - 100%)	19	(5.2-67)
				2			
Total		68	1,251	5.6%	(4.4 - 7.1%)		

a) Due to emigration or limited follow-up time, 72 individuals were censored in the analysis.

 b) Estimated risk of death before five years of age, calculated by the Nelson-Aalen's cumulative hazard estimate. For comparison, the risk of death before five years of age in children without chromosomal aberration was 0.3% for individuals without CHD, 4.0% for individuals with persistent ductus arteriosus, atrial septal defect or ventricular septal defect, and 18% for those with remaining types of CHD.


c) Cox' proportional hazard ratio estimate, using live births with Down's syndrome without CHD and without ECM as reference. Estimates are adjusted for year of birth.


d) Isolated atrial septal defects, isolated ventricular septal defects, and combined atrial septal defects and ventricular septal defects.

e) Tetralogy of Fallot, double outlet right ventricle, conotruncal ventricular septal defects, aortic hypoplasia, truncus arteriosus, and interrupted aortic arch.

f) Heterotaxia, anomalous pulmonary venous return, aortic valve stenosis, aortic valve insufficiency, other malformations of the aortic valve, coarctation of the aorta, Ebstein's anomaly, pulmonary atresia, pulmonary valve stenosis, mitral valve insufficiency, and unspecified CHD.

CHD, congenital heart defect; CI, Confidence interval; ECM, extracardiac malformations; HR, hazard ratio.







Time trend for total birth prevalence (per 10,000 births) of Down's syndrome by year of birth, based on 953,450 births in Norway 1994-2009.

Footnote: AVSD, atrioventricular septal defect; CHD, congenital heart defects; TOPFA: Termination of Pregnancy for Foetal Anomaly.

465x275mm (120 x 120 DPI)





	ICD-10	ICD-9	ICD-8
Nervous system malformations	Q00-Q18, Q30-Q64	740.0-744.9, 748.0-749.9, 759.0-759.2	740.0-745.9, 748.0-749.9, 758.0-758.3
	Q00-Q07	740.0-742.9	740.0-743.9
Eyes, ears, face, neck malformations	Q10-Q18	743.0-744.9	744.0-745.9
Respiratory system malformations	Q30-Q34	748.0-748.9	748.0-748.9
Cleft lip-palate	Q35-Q37	749.0-749.9	749.0-749.9
Digestive system malformations	Q38-Q45	750.0-751.9	750.0-751.9
Oesophageal atresia/ stenosis	Q39	750.3-750.4	750.2
Small intestine	Q41	751.1	751.1
Duodenal atresia/ stenosis	Q41.0	b	b
Large intestine	Q42	751.2	751.2
Rectal/ anal atresia/ stenosis	Q42.0-Q42.3 °	b	b
Hirschsprung's disease	Q43.1, P76.1, P76.8, P76.9 ^d	751.3	751.3
Genital organs malformations	Q50-Q56	752.0-752.9	752.0-752.9
Urinary system malformations	Q60-Q64	753.0-753.9	753.0-753.9
	ICD-9		g children with Down's syndrome.
 No representative codes in ICD-8 and I Rectal and anal stenoses and atresia, with ICD-10 codes suggesting transitory into misclassified Hirschsprung's disease, b was identified, and for this child the diagonal statement of the statement of	ith and without fistulas, were estinal obstruction of new-bo because the clinical presentate agnosis Hirschsprung's disea	e combined into one category. orn (P76.1, P76.8, and P76.9) where inc ion may be unspecific initially. One inf se was verified in the CVDNOR.	luded to identify possibly
 No representative codes in ICD-8 and I Rectal and anal stenoses and atresia, with ICD-10 codes suggesting transitory into misclassified Hirschsprung's disease, b 	ith and without fistulas, were estinal obstruction of new-bo because the clinical presentate agnosis Hirschsprung's disea	e combined into one category. orn (P76.1, P76.8, and P76.9) where inc ion may be unspecific initially. One inf se was verified in the CVDNOR.	luded to identify possibly
 No representative codes in ICD-8 and I Rectal and anal stenoses and atresia, with ICD-10 codes suggesting transitory into misclassified Hirschsprung's disease, b was identified, and for this child the diagonal statement of the statement of	ith and without fistulas, were estinal obstruction of new-bo because the clinical presentate agnosis Hirschsprung's disea	e combined into one category. orn (P76.1, P76.8, and P76.9) where inc ion may be unspecific initially. One inf se was verified in the CVDNOR.	luded to identify possibly
 No representative codes in ICD-8 and I Rectal and anal stenoses and atresia, with ICD-10 codes suggesting transitory into misclassified Hirschsprung's disease, b was identified, and for this child the diagonal statement of the statement of	ith and without fistulas, were estinal obstruction of new-bo because the clinical presentate agnosis Hirschsprung's disea	e combined into one category. orn (P76.1, P76.8, and P76.9) where inc ion may be unspecific initially. One inf se was verified in the CVDNOR.	luded to identify possibly
 No representative codes in ICD-8 and I Rectal and anal stenoses and atresia, with ICD-10 codes suggesting transitory into misclassified Hirschsprung's disease, b was identified, and for this child the diagonal statement of the statement of	ith and without fistulas, were estinal obstruction of new-bo because the clinical presentate agnosis Hirschsprung's disea	e combined into one category. orn (P76.1, P76.8, and P76.9) where inc ion may be unspecific initially. One inf se was verified in the CVDNOR.	luded to identify possibly
 No representative codes in ICD-8 and I Rectal and anal stenoses and atresia, with ICD-10 codes suggesting transitory into misclassified Hirschsprung's disease, b was identified, and for this child the diagonal statement of the statement of	ith and without fistulas, were estinal obstruction of new-bo because the clinical presentate agnosis Hirschsprung's disea	e combined into one category. orn (P76.1, P76.8, and P76.9) where inc ion may be unspecific initially. One inf se was verified in the CVDNOR.	luded to identify possibly
 No representative codes in ICD-8 and I Rectal and anal stenoses and atresia, with ICD-10 codes suggesting transitory into misclassified Hirschsprung's disease, b was identified, and for this child the diagonal statement of the statement of	ith and without fistulas, were estinal obstruction of new-bo because the clinical presentate agnosis Hirschsprung's disea	e combined into one category. orn (P76.1, P76.8, and P76.9) where inc ion may be unspecific initially. One inf se was verified in the CVDNOR.	luded to identify possibly
 No representative codes in ICD-8 and I Rectal and anal stenoses and atresia, with ICD-10 codes suggesting transitory into misclassified Hirschsprung's disease, b was identified, and for this child the diagonal statement of the statement of	ith and without fistulas, were estinal obstruction of new-bo because the clinical presentate agnosis Hirschsprung's disea	e combined into one category. orn (P76.1, P76.8, and P76.9) where inc ion may be unspecific initially. One inf se was verified in the CVDNOR.	luded to identify possibly